Agios Pharmaceuticals, Inc. Stock News

Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025 Strong U.S. demand for AQVESME in thalassemia continues, with 619 cumulative prescriptions with completed start forms from REMS-certified physicians, plus 48 additional prescriptions with start forms in process as...

Agios announces new clinical data across company's rare hematology portfolio that will be featured in oral and poster presentations during ASH 2026.

FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease FDA classified Agios' response to the information request as a major amendment to the mitapivat sNDA, resulting in a three-month review extension Mitapivat sNDA was submitted under the FDA's accelerated approval pathway and granted Priority Review, with an original PDUFA go...

Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025 Strong U.S. commercial launch of AQVESME in thalassemia, with 442 cumulative prescriptions written as of June 30, 2026 sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, ...

Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled.

Agios ​Pharmaceuticals said on Tuesday it ‌will stop development of its sickle cell disease treatment, ​sending its shares down ​14% in premarket trading.